Approved HCV Drugs
Approved HCV Drugs
AASLD 2014: Sofosbuvir/Ledipasvir and AbbVie 2D Cure Most People with HCV Genotype 4
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 12 November 2014 00:00
- Written by Liz Highleyman
Sofosbuvir/ledipasvir (Harvoni) without ribavirin and AbbVie's 2D regimen (paritaprevir/ritonavir/ombitasvir) both produced high sustained virological response rates for patients with hepatitis C virus (HCV) genotype 4, according to a pair of studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.
AASLD 2014: Sustained Response to HCV Treatment Reduces Mortality, Liver Cancer, Liver Transplants
- Details
- Category: Approved HCV Drugs
- Published on Sunday, 09 November 2014 00:00
- Written by Liz Highleyman
People who achieve sustained virological response (SVR) when treated with interferon-based therapy for hepatitis C have a lower risk of death, are less likely to develop liver cancer, and need fewer liver transplants than those who were treated but not cured, according to results from a meta-analysis of more than 34,000 patients presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.
ICAAC 2014: Telaprevir and Boceprevir Have Limited Efficacy in Real-world Use
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 23 September 2014 00:00
- Written by Liz Highleyman
Hepatitis C treatment using the first-generation HCV protease inhibitors telaprevir (Incivek or Incivo) or boceprevir (Victrelis) cured only 71% of people with easier-to-treat HCV genotypes 1b, falling to 47% for those with genotype 1a, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this month in Washington, DC.
AASLD 2014: Sofosbuvir/Ledipasvir Cures Nearly All Genotype 1 HIV/HCV Coinfected Patients
- Details
- Category: Approved HCV Drugs
- Published on Sunday, 09 November 2014 00:00
- Written by Liz Highleyman
All but 1 participant treated with a coformulation of sofosbuvir and ledipasvir (Harvoni) achieved sustained virological response at 12 weeks post-treatment in a study looking at traditionally hard-to-treat HIV/HCV coinfected patients, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.
Vertex to Discontinue Sale of Telaprevir (Incivek) for Hepatitis C
- Details
- Category: Approved HCV Drugs
- Published on Friday, 22 August 2014 00:00
- Written by HIVandHepatitis.com
Vertex Pharmaceuticals announced last week that it will stop selling its HCV protease inhibitor telaprevir (Incivek or Incivo) as of October 16, 2014. While the first generation direct-acting antivirals are more effective than pegylated interferon plus ribavirin alone, they are no match for newer drugs such as Gilead Sciences' sofosbuvir (Sovaldi) or AbbVie's forthcoming "3D" regimen in terms of efficacy or tolerability.
Web Design and Development by